Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation.

Biomaterials - 1 Dec 2023

Sung Yejin, Hong Seung Taek, Jang Mihue, Kim Eun Sun, Kim Chansoo, Jung Youngmee, Youn Inchan, Chan Kwon Ick, Cho Seung-Woo, Ryu Ju Hee

Abstract excerpt

Anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, therapy has significantly improved the clinical outcomes of patients with colorectal cancer, but the response to cetuximab can vary widely among individuals. We thus need strategies for predicting the response to this therapy. However, the current methods are unsatisfactory in their predictive power. Cetuximab can promote the internalization and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to Mutation

Source

Identifiers

PMID: 37977005
DOI: 10.1016/j.biomaterials.2023.122382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation.PMID 37977005Read ↗

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.Semantic proximity Read ↗

Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.Semantic proximity Read ↗

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.Semantic proximity Read ↗

Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.Semantic proximity Read ↗

EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.Semantic proximity Read ↗

The TCF3-FBXL18 axis regulates KRAS stability to determine cetuximab response in colorectal cancerSemantic proximity Read ↗

Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis.Semantic proximity Read ↗

NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancerSemantic proximity Read ↗

Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells.Semantic proximity Read ↗

Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.Semantic proximity Read ↗

Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.Semantic proximity Read ↗

Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.